Company research
CytoDyn Inc.
CIK 1175680Updated Sep 24, 2026
SecurityCYDY · OTC · equity
Name history
CYTODYN INC · through Apr 13, 2016REXRAY CORP · through Nov 12, 2003
CYDY price & chart
Loading TradingView…
OTC:CYDY on TradingView ↗About the company
The Company is a clinical stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for its potential in solid-tumor oncology.
In the news
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab ↗
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 13,973,000Source | 18,047,000Source | 11,136,000Source | 11,292,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,852,000Source | 11,903,000Source | 3,110,000Source | 2,541,000Source |
| Inventory, NetUSD | — | — | 0Source | — |
| Assets, CurrentUSD | 13,878,000Source | 17,878,000Source | 10,815,000Source | 10,805,000Source |
| Operating Lease, Right-of-Use AssetUSD | 73,000Source | 130,000Source | 264,000Source | 400,000Source |
| Other Assets, NoncurrentUSD | 95,000Source | 169,000Source | 321,000Source | 487,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 123,691,000Source | 114,089,000Source | 127,894,000Source | 120,793,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,374,000Source | 1,249,000Source | 1,059,000Source | 919,000Source |
| Additional Paid in CapitalUSD | 819,393,000Source | 790,495,000Source | 773,714,000Source | 731,270,000Source |
| Retained Earnings (Accumulated Deficit)USD | -930,485,000Source | -887,786,000Source | -891,531,000Source | -841,690,000Source |
| Stockholders' Equity Attributable to ParentUSD | -109,718,000Source | -96,042,000Source | -116,758,000Source | -109,501,000Source |
| Liabilities and EquityUSD | 13,973,000Source | 18,047,000Source | 11,136,000Source | 11,292,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 53,727,000Source | 70,518,000Source | 84,182,000Source | 119,796,000Source |
| Operating Lease, Liability, CurrentUSD | 23,000Source | 141,000Source | 142,000Source | 139,000Source |
| Accounts Payable, CurrentUSD | 13,155,000Source | 14,692,000Source | 29,561,000Source | 62,725,000Source |
| Operating Lease, Liability, NoncurrentUSD | 53,000Source | 0Source | 141,000Source | 283,000Source |
| Other Liabilities, NoncurrentUSD | 43,571,000Source | 43,571,000Source | 43,571,000Source | — |
| Additional Financial Items | ||||
| Dividends Payable, CurrentUSD | 9,647,000Source | 8,269,000Source | 6,791,000Source | 5,308,000Source |
| Dividends PayableUSD | — | — | — | 5,417,000Source |
| Long-term DebtUSD | 38,340,000Source | 45,351,000Source | 45,020,000Source | 45,729,000Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,630,000Source | 1,612,000Source | 2,415,000Source | 4,275,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -17,252,000Source | -8,765,000Source | -10,982,000Source | -25,110,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 17,201,000Source | 10,854,000Source | 11,748,000Source | 29,927,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -51,000Source | 2,089,000Source | 766,000Source | 4,817,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,852,000Source | 11,903,000Source | 9,814,000Source | 9,048,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 22,000Source | 25,000Source | 45,000Source | 19,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | — | — | 572,000Source | 9,747,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 407,000Source | 1,511,000Source | 2,195,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | 100,000Source |
| DepreciationUSD | — | — | 29,000Source | — |
| Dividends Payable, CurrentUSD | 9,647,000Source | 8,269,000Source | 6,791,000Source | 5,308,000Source |
| Dividends PayableUSD | — | — | — | 5,417,000Source |
| Gain (Loss) on Sale of DerivativesUSD | 0Source | -852,000Source | -236,000Source | -8,750,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -13,374,000Source | — |
| General and Administrative ExpenseUSD | 7,449,000Source | 7,260,000Source | 10,789,000Source | 17,136,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | — | 20,633,000Source |
| Investment Income, InterestUSD | 257,000Source | 565,000Source | — | — |
| LitigationSettlementLossUSD | 15,430,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -44,180,000Source | 2,261,000Source | -51,324,000Source | -86,736,000Source |
| Proceeds from Issuance of Common StockUSD | 900,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 149,000Source | 106,000Source | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | -6,000Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source |
| Operating Income (Loss)USD | -38,575,000Source | 9,661,000Source | -18,058,000Source | -40,576,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Earnings Per Share, BasicUSD per share | -0.03Source | 0Source | -0.05Source | -0.1Source |
| Earnings Per Share, DilutedUSD per share | -0.03Source | 0Source | -0.05Source | -0.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,289,302,000Source | 1,205,755,000Source | 969,509,000Source | 836,528,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,289,302,000Source | 1,242,922,000Source | 969,509,000Source | 836,528,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | — | 100,000Source |
| Costs and ExpensesUSD | 38,575,000Source | -9,661,000Source | 18,058,000Source | 40,576,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 17,000Source | 18,000Source | 29,000Source | 175,000Source |
| General and Administrative ExpenseUSD | 7,449,000Source | 7,260,000Source | 10,789,000Source | 17,136,000Source |
| Investment Income, InterestUSD | 257,000Source | 565,000Source | — | — |
| LitigationSettlementLossUSD | 15,430,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -44,180,000Source | 2,261,000Source | -51,324,000Source | -86,736,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | 1,481,000Source | 1,483,000Source | 1,483,000Source | 1,495,000Source |
| Research and Development ExpenseUSD | — | — | 7,240,000Source | 2,632,000Source |
Offerings
Registration 333-295250
Filing attachments
ck0001175680-ex99_1.htm · 8-K · 2026-04-30
EX-99.1 2 ck0001175680-ex99_1.htm EX-99.1 Leronlimab - A Novel Therapeutic in CCR5+ Immuno-Oncology CYTODYN. COM / OTCMKTS: CYDY FORWARD LOOKING STATEMENT This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans…
Read attachment ↗cydy-20251103xex99d1.htm · 8-K · 2025-11-03
EX-99.1 3 cydy-20251103xex99d1.htm EX-99.1 Exhibit 99.1 CytoDyn Secures $30 Million Commitment from Yorkville Advisors VANCOUVER, Washington, November 3, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorecta…
Read attachment ↗cydy-20250502xex99d1.htm · 8-K · 2025-05-06
EX-99.1 3 cydy-20250502xex99d1.htm EX-99.1 Exhibit 99.1 CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer VANCOUVER, Washington, May 6, 2025 - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E. Hoffman has been appointed as Chief Financial Officer, effective May 15, 2025. He will take over the CFO position…
Read attachment ↗